MeiraGTx (MGTX) Insider Stuart Naylor Buys 70,000 Shares
Stuart Naylor, Chief Scientist at MeiraGTx, acquired 70,000 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Stuart Naylor, CHIEF SCI OFCR, OPHTHALMOLOGY at MeiraGTx Holdings plc ($MGTX), bought 70,000 shares on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MGTX is up 20.7% after 1 week, up 6.7% after 1 month and down 19.5% to date (from the $11.53 close on Jun 25, 2026).
MGTX
MeiraGTx Holdings plc
Key Points
- Stuart Naylor, Chief Scientist at MeiraGTx Holdings, purchased 70,000 shares on June 25, 2026.
- Shares of NasdaqGS:MGTX traded at $12.54 on Tuesday, with a market cap of $1.12 billion.
- Analysts maintain a strong buy consensus with a mean target price of $28.25 for MeiraGTx.
Get $MGTX trade alerts by text
We text you when insiders, Congress or big funds trade $MGTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MeiraGTx Holdings plc alert may contain errors. Disclosures
On June 25, 2026, Stuart Naylor, the Chief Scientist of Ophthalmology at MeiraGTx Holdings plc, purchased 70,000 shares of the company's stock. The transaction was not part of a pre-planned trading program, and the shares were acquired at no cost, according to the filing. This move adds to the insider activity at the company as other executives also made significant purchases on the same day.
Insider Buying and Selling at MeiraGTx Holdings plc
In addition to Stuart Naylor, several other insiders at MeiraGTx Holdings made notable purchases. President and CEO Alexandria Forbes acquired 980,000 shares, while General Counsel Robert Wollin and Chief Medical Officer Robert Zeldin each bought 100,000 shares. CFO and COO Richard Giroux also bought 980,000 shares. These transactions suggest a strong internal confidence in the company's prospects.
MeiraGTx Holdings plc Stock Down 5.4%
Shares of MeiraGTx Holdings, traded under the ticker MGTX on the NasdaqGS, were priced at $12.54 on Tuesday. The company has a market capitalization of approximately $1.12 billion. MeiraGTx's forward P/E ratio is not meaningful as it is currently not profitable. The stock's 52-week range is between $6.31 and $12.28, with a 50-day moving average of $9.86 and a 200-day moving average of $8.52. The company's current and quick ratios indicate limited short-term liquidity.
Analysts Set New Price Targets
Analysts continue to show strong support for MeiraGTx Holdings. On May 15, 2026, RBC Capital maintained its 'buy' rating with a price target of $25. Piper Sandler also maintained a 'buy' rating with a $30 target on April 22. The consensus among analysts is a 'strong buy', with a mean target price of $28.25 based on eight analyst opinions.
About MeiraGTx Holdings
MeiraGTx Holdings plc is a biotechnology company based in New York, New York. It focuses on developing genetic medicines for treating serious diseases, particularly in ocular and neurodegenerative fields. The company is advancing various therapies, including treatments for inherited retinal diseases and Parkinson's disease. Founded in 2015, MeiraGTx collaborates with major partners like Johnson & Johnson to enhance its research and development efforts.
Bottom Line
Stuart Naylor's purchase of MeiraGTx Holdings shares is part of a broader insider buying trend at the company, indicating confidence in its future. Investors will be watching how these insider moves align with the company's performance and upcoming earnings report on August 13, 2026. As always, it's important to remember that insider transactions are disclosed after the fact and don't necessarily predict future stock performance.
Related Filing Alerts
Source: Stuart Naylor's Form 4 filing on $MGTX (Jun 25, 2026). Find the original filing: MGTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts